Zura Bio director reports stock option holdings

Zura Bio Ltd director Parvinder Thiara reported initial derivative holdings in the company.

Accepted by SEC EDGAR 01/27/2026 - 06:44 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Zura Bio Ltd director Parvinder Thiara reported initial derivative holdings in the company. This Form 3 shows two stock option positions over Class A ordinary shares.

The director holds a share option for 48,149 Class A ordinary shares at an exercise price of $3.98, expiring on 01/24/2034, which is described as immediately exercisable. A second share option covers 117,000 Class A ordinary shares at an exercise price of $2.76, expiring on 12/09/2034, also reported as immediately exercisable.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Thiara Parvinder

Role Director

Type	Security	Shares	Price	Value
Holding	Share Option (Right to Buy)	--	--	--
Holding	Share Option (Right to Buy)	--	--	--

Holdings: Share Option (Right to Buy) — 165,149 contracts (Direct)

Footnotes (1)

1. F1. Immediately exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Zura Bio (ZURA) disclose in this Form 3 filing?

The Form 3 shows director Parvinder Thiara reporting initial beneficial ownership of two sets of share options over Zura Bio Class A ordinary shares, including amounts, exercise prices, and expiration dates.

How many Zura Bio (ZURA) options does director Parvinder Thiara report?

Parvinder Thiara reports a share option over 48,149 Class A ordinary shares at $3.98 and another option over 117,000 Class A ordinary shares at $2.76, both listed as beneficially owned directly.

When do Parvinder Thiara’s Zura Bio (ZURA) options expire?

One Zura Bio share option held by Parvinder Thiara expires on 01/24/2034. The second option expires on 12/09/2034. Both options relate to Class A ordinary shares and are reported as immediately exercisable.

Are Parvinder Thiara’s reported Zura Bio (ZURA) options immediately exercisable?

Yes. A footnote states the share options are immediately exercisable. This applies to both the 48,149-share option at $3.98 and the 117,000-share option at $2.76, as disclosed in the derivative securities table.

Is this Zura Bio (ZURA) Form 3 a report of trades or of existing holdings?

This Form 3 reports existing beneficial holdings of derivative securities by director Parvinder Thiara. The transactions are coded as holdings, not purchases or sales, and show total options beneficially owned following the reported event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Thiara Parvinder

(Last) (First) (Middle)

C/O ZURA BIO LIMITED

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NV 89014

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/23/2026

3. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	01/24/2034	Class A Ordinary Shares	48,149	$3.98	D
Share Option (Right to Buy)	(1)	12/09/2034	Class A Ordinary Shares	117,000	$2.76	D

Explanation of Responses:

1. Immediately exercisable.

	/s/ Kim Davis, Attorney-in-Fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.